Sertindole causes distinct electrocardiographic T-wave morphology changes

European Neuropsychopharmacology

Volumn 19, Issue 10, 2009, Pages 702-707

  Nielsen, Jimmi ^a   Graff, Claus ^b   Hardahl, Thomas ^b   Andersen, Mads P ^b   Kristoffersen, Jens ^c   Struijk, Johannes J ^b   Toft, Egon ^b   Meyer, Jonathan M ^d  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b AALBORG UNIVERSITY   (Denmark)

^c Institute of Clinical Research   (Denmark)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antipsychotics; QTc; Sertindole; Sudden death; T wave; Torsade de pointes

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE; ZUCLOPENTHIXOL;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG MONITORING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; FEMALE; HEART ARRHYTHMIA; HEART RATE; HUMAN; MALE; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; SCHIZOPHRENIA; SIDE EFFECT; T WAVE;

ADULT; ANTIPSYCHOTIC AGENTS; COHORT STUDIES; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; IMIDAZOLES; INDOLES; MALE; SCHIZOPHRENIA;

EID: 69049119104     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2009.04.011     Document Type: Article

References (25)

1. Andersen M.P., Xue J.Q., Graff C., Kanters J.K., Toft E., and Struijk J.J. New descriptors of T-wave morphology are independent of heart rate. J. Electrocardiol. 41 (2008) 557-561
2. Dogan A., Tunc E., Varol E., Ozaydin M., and Ozturk M. Comparison of the four formulas of adjusting QT interval for the heart rate in the middle-aged healthy Turkish men. Ann. Noninvasive Electrocardiol. 10 (2005) 134-141
3. Eckardt L., Breithardt G., and Haverkamp W. Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation. J. Pharmacol. Exp. Ther. 300 (2002) 64-71
4. FDA Guidance for Industry: E14 Clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. 2005.
5. Fontaine K.R., Heo M., Harrigan E.P., Shear C.L., Lakshminarayanan M., Casey D.E., and Allison D.B. Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Res. 101 (2001) 277-288
6. Glass G.V. Integrating findings: the meta-analysis of research. Rev. Res. Educ. 5 (1977) 351-379
7. Graff C., Andersen M.P., Xue J.Q., Hardahl T.B., Kanters J.K., Toft E., Christiansen M., Jensen H.K., and Kanters J.J. Identifying Drug-Induced Repolarization Abnormalities from Distinct ECG Patterns in Congenital Long QT Syndrome: A Study of Sotalol Effects on T-Wave Morphology. Drug Saf. 32 (2009) 599-611
8. Haverkamp W., Eckhardt L., Matz J., and Frederiksen K. Sertindole: Cardiac electrophysiological profile. Int. J. Psychiatry Clin. Pract. 6 (2002) 11-20
9. Henderson D.C. Managing weight gain and metabolic issues in patients treated with atypical antipsychotics. J. Clin. Psychiatry 69 (2008) e04
10. Hohnloser S.H. Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management. Am. J. Cardiol. 80 (1997) 82G-89G
11. Kanters J.K., Graff C., Andersen M.P., Hardahl T., Toft E., Christiansen M., Bloch Thomsen P.E., and Struijk J.J. Long QT syndrome genotyping by electrocardiography: fact, fiction, or something in between?. J. Electrocardiol. 39 (2006) S119-S122
12. Moore N. Higher cardiovascular mortality with sertindole in ADROIT: a signal not confirmed. Int. J. Psychiatry Clin. Pract. 6 (2002) S3-S6
13. Moore N., Hall G., Sturkenboom M., Mann R., Lagnaoui R., and Begaud B. Biases affecting the proportional reporting ratio (PPR) in spontaneous reports pharmacovigilance databases: the example of sertindole. Pharmacoepidemiol. Drug Saf. 12 (2003) 271-281
14. Peuskens J., Moore N., Azorin J.M., Toumi M., and Cochran J. The European sertindole safety and exposure survey: a follow-up study of 8600 patients. Pharmacoepidemiol. Drug Saf. 16 (2007) 804-811
15. Peuskens J., Tanghoj P., and Mittoux A. The Sertindole Cohort Prospective (SCoP) study: rationale, design and methodology. Pharmacoepidemiol. Drug Saf. 17 (2008) 425-433
16. Pezawas L., Quiner S., Moertl D., Tauscher J., Barnas C., Kufferle B., Wolf R., and Kasper S. Efficacy, cardiac safety and tolerability of sertindole: a drug surveillance. Int. Clin. Psychopharmacol. 15 (2000) 207-214
17. Redfern W.S., Carlsson L., Davis A.S., Lynch W.G., MacKenzie I., Palethorpe S., Siegl P.K., Strang I., Sullivan A.T., Wallis R., Camm A.J., and Hammond T.G. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res. 58 (2003) 32-45
18. Shah R.R., and Hondeghem L.M. Refining detection of drug-induced proarrhythmia: QT interval and TRIaD. Heart Rhythm. 2 (2005) 758-772
19. Taylor D.M. Antipsychotics and QT prolongation. Acta Psychiatr. Scand. 107 (2003) 85-95
20. Thomsen M.B., Volders P.G., Stengl M., Spatjens R.L., Beekman J.D., Bischoff U., Kall M.A., Frederiksen K., Matz J., and Vos M.A. Electrophysiological safety of sertindole in dogs with normal and remodeled hearts. J. Pharmacol. Exp. Ther. 307 (2003) 776-784
21. Thornton C.C., and Wendkos M.H. EKG T-wave distortions among thioridazine-treated psychiatric inpatients (some correlates of the incidence and severity). Dis. Nerv. Syst. 32 (1971) 320-323
22. Titier K., Canal M., Deridet E., Abouelfath A., Gromb S., Molimard M., and Moore N. Determination of myocardium to plasma concentration ratios of five antipsychotic drugs: comparison with their ability to induce arrhythmia and sudden death in clinical practice. Toxicol. Appl. Pharmacol. 199 (2004) 52-60
23. Wehnert A. The European Post-marketing Observational Serdolect (EPOS) Project: increasing our understanding of schizophrenia therapy. Int. Clin. Psychopharmacol. 13 Suppl 3 (1998) S27-S30
24. Wendkos M.H. The Significance of Electrocardiographic Changes Produced by Thioridazine. J New drugs 4 (1993) 322-332
25. Wilton L.V., Heeley E.L., Pickering R.M., and Shakir S.A. Comparative study of mortality rates and cardiac dysrhythmias in post-marketing surveillance studies of sertindole and two other atypical antipsychotic drugs, risperidone and olanzapine. J. Psychopharmacol. 15 (2001) 120-126